Bedrijfsoverzicht
NeurAxis, Inc. is a medical technology firm dedicated to the development and commercialization of neuromodulation therapies designed to treat chronic and debilitating conditions affecting both children and adults within the United States. The company's primary product offering is the IB-Stim system, a percutaneous electrical nerve field stimulation device specifically engineered for patients aged eight years and older. Operating within the healthcare sector and the biotechnology industry, NeurAxis functions as a specialized innovator targeting unmet needs in pain management and neurological disorders. With a market capitalization of $76.52M, annual revenue of $3.57M, and an employee count of 24, the organization operates as a small-cap entity with a limited operational footprint. These valuation and revenue figures indicate that the company is in an early-stage growth phase, where market capitalization is heavily influenced by the potential of its pipeline rather than current cash flow generation. The modest revenue base relative to the market cap suggests a high reliance on future product milestones to unlock value, while the small workforce reflects a capital-efficient approach typical of early-stage biotechnology ventures.
Financiële gezondheid
The company reported total revenue of $3.57M over the trailing twelve months, yet recorded a net income of -$8,615,152 and an EBITDA of -$7,139,839. The significant disparity between the $3.57M revenue and the -$8.6M net loss reveals a highly leveraged cost structure where operating expenses and research costs substantially exceed gross profit generation. Free cash flow stood at -$3,857,785, indicating that the company is currently burning cash to fund operations and development activities, which limits immediate financial flexibility for external expansion. Despite the negative earnings, the gross margin remains robust at 84.2%, suggesting that the cost of goods sold is low relative to the pricing of the IB-Stim system. However, the operating margin is severely depressed at -177.3% and the profit margin is negative at -218.5%, highlighting the substantial overhead costs associated with maintaining a biotechnology company before achieving commercial profitability. On the balance sheet, the company holds $4.97M in cash against $426,610 in debt, resulting in a debt-to-equity ratio of 12.55. While the cash position covers short-term obligations, the high debt-to-equity ratio signals a capital structure that is heavily reliant on equity financing rather than traditional debt leverage. Liquidity is supported by a current ratio of 2.05, which indicates that current assets are more than twice the value of current liabilities, providing a comfortable buffer against short-term solvency risks. Return on Equity is reported at -285.4% and Return on Assets at -80.6%, metrics that reflect the dilutive effect of losses on shareholder value and the inefficiency of asset utilization in generating profits during this developmental stage.
Waarderingsbeoordeling
The valuation metrics present a complex picture due to the company's lack of profitability, with a Trailing P/E Ratio of N/A and a Forward P/E of -342.00. The negative forward P/E implies that analysts or the market expects earnings to remain negative in the near term, making traditional earnings-based valuation methods inapplicable for assessing intrinsic value at this stage. The price-to-book ratio stands at 21.44, which indicates that the market is pricing the company at a significant premium over its tangible book value, reflecting high expectations for the success of its neuromodulation therapies. This price-to-sales ratio is also 21.44, further emphasizing that the stock price is driven entirely by future potential rather than current sales performance. The EV/EBITDA multiple is -10.08, another metric that underscores the company's loss-making status and the difficulty in valuing it using standard enterprise valuation frameworks. Historically, the stock has exhibited significant volatility, trading between a 52-week low of $1.33 and a 52-week high of $7.97. Assuming a current market price near the mid-range of historical trading, the stock trades at a level that reflects high uncertainty regarding the timeline to commercialization. The beta coefficient is 1.89, indicating that the stock's price volatility is nearly double that of the broader market, making it a high-risk investment suitable only for portfolios with a high tolerance for equity market fluctuations.
Growth & Income
Revenue growth for the company accelerated to 27.2% year-over-year, demonstrating successful sales expansion or market penetration for the IB-Stim system. Earnings growth is listed as N/A due to the company's consistent net losses, meaning that while top-line sales are improving, the bottom line has not yet responded with profitability. Since the earnings are negative, they are growing slower than revenue in a mathematical sense regarding absolute value, but the primary implication is that the company has not yet reached the breakeven point required to sustain earnings growth on an absolute basis. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders. This approach is consistent with biotechnology firms that reinvest all available capital, including the $4.97M cash reserves, back into research, development, and operational scaling to accelerate product approval and market adoption. The overall growth and income profile is characterized by strong revenue expansion coupled with significant cash burn and a complete absence of current income distribution, positioning the stock as a pure-play speculative vehicle dependent on future clinical successes.